WuXi PharmaTech Announces Shareholder Resolutions Adopted at 2012 Annual General Meeting

SHANGHAI, Nov. 6, 2012 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX) today announced shareholder resolutions adopted at its annual general meeting of shareholders held in Hong Kong on November 6, 2012.

At the meeting, WuXi PharmaTech shareholders approved the re-election of incumbent Class B directors Xuesong (Jeff) Leng, Zhaohui Zhang, and Ning Zhao, each to serve a three-year term.

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to help its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec.

For more information, please contact:




WuXi PharmaTech (Cayman) Inc.


Ronald Aldridge (for investors)


Director of Investor Relations


Tel: +1-201-585-2048


Email: [email protected]




Aaron Shi (for the media)


WuXi PharmaTech (Cayman) Inc.


Tel: +86-21-5046-4362


Email: [email protected]


 

SOURCE WuXi PharmaTech (Cayman) Inc.

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.